{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-22-000051","form_type":"8-K/A","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.098190+00:00","generated_at":"2026-06-24T01:48:30.484527+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Halozyme completes Antares acquisition for $5.60/sh; total consideration ~$1.0457B","bullets":["Aggregate purchase consideration $1,045.7M; each Antares share converted into $5.60 cash.","Pro forma combined 2021 revenue $627.3M, net income $286.2M; basic EPS $2.04.","Pro forma Q1 2022 revenue $158.8M, net income $36.2M; basic EPS $0.26.","Financing includes $250M term loan and $350M revolving credit facility from BofA.","Nonrecurring acquisition-related costs of $40.5M expensed in pro forma statements."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-22-000051","json":"https://secwatch.observer/filing/0001159036-22-000051.json","markdown":"https://secwatch.observer/filing/0001159036-22-000051.md","text":"https://secwatch.observer/filing/0001159036-22-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000051/0001159036-22-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000051/halo-20220524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:48:30.484527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}